We are currently in the process of updating our web site to reflect the announced plans to change our company name from Algernon Pharmaceuticals to Algernon Health. Please visit again soon as these changes continue to take effect across the entire web site.
Company Profile
Algernon Pharmaceuticals is a Canadian clinical stage drug development and repurposing company investigating multiple drugs for unmet global medical needs. Algernon Pharmaceuticals is the parent company of a newly created private equity subsidiary called Algernon NeuroScience, that is advancing a program investigating a proprietary form of DMT for stroke and traumatic brain injury (TBI). The Company recently closed on its agreement with Seyltx Inc., a privately owned U.S. based drug development company, for the acquisition of Algernon’s NP-120 Ifenprodil research program to treat chronic cough and idiopathic pulmonary fibrosis, and also maintains a research program for chronic kidney disease.
Latest Presentation
Corporate Fact Sheet
View Corporate Fact SheetIndustry Classifications
Sector:
Biotechnology
Industry:
Drug Development
NAICS:
Research and Development in the Physical, Engineering, and Life Sciences (541710)
SIC:
Commercial Physical and Biological Research (8731)
Contact Information
Investor Relations
Christopher J. Moreau
Chief Executive Officer
T: 604-398-4175
chris@algernonpharmaceuticals.com
Company Contact
Algernon Pharmaceuticals Inc.
601 West Broadway
Suite 400
Vancouver, BC V5Z 4C2
Canada
T: 604-398-4175
info@algernonpharmaceuticals.com
